Full-Time

Head – Market Access and Patient Services

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States.

Category
Operations Consulting
Consulting
Requirements
  • Undergraduate degree required, MBA and/or relevant post graduate qualifications preferred
  • 15+ years of pharmaceutical industry experience and minimum of 10 years in market access leadership positions, including building and leading payer account teams
  • Established network of Payer and PBM relationships
  • Prior people management experience – especially managing payer account teams
  • Track record successfully negotiating access for prescription products in competitive therapeutic areas in the US
  • Possess strong ‘executive presence’ and excellent communication skills
  • Demonstrated ability to lead and influence in rapidly changing environment
  • Travel - Position requires up to 30% travel
Responsibilities
  • Serve as the primary market access point of contact for the US region; ensure launch and pipeline assets are supported.
  • Build the access strategy, payer account, field reimbursement, patient services and specialty pharmacy distribution teams that will be needed to ensure a successful launch of Avexitide®, for Post Bariatric Hypoglycemia
  • Champion pricing and reimbursement requirements throughout organization and ensure alignment between all stakeholders internally; this includes identifying payer unmet needs, assessing pricing potential, identifying access challenges and ways to overcome, overseeing tactical execution plans, supporting payer negotiations as needed, etc.
  • Be accountable for the development of US market access deliverables, negotiation strategies, and national/regional market access tactics to secure price and reimbursement
  • Collaborate with internal stakeholders (Marketing, Medical Affairs, Regulatory, Legal and Finance), to ensure that plans are fit-for-purpose
  • Design a tailored patient support program to enable broad and timely patient access.
  • Provide Market Access perspectives in support of business development initiatives
  • Develop pre- and post-approval engagement strategies.
  • Initiate, maintain, and tactfully influence relationships with various medical and non-medical stakeholders.
  • Mentor individuals on the US Market Access and Reimbursement team • Actively contribute to the annual brand planning, forecasting, and budgeting process.
  • Other duties as assigned.
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients through a randomized, double-blind, placebo-controlled study. They are also conducting the PEGASUS trial to assess AMX0035's safety and effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-38%

1 year growth

-33%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.

Help us improve and share your feedback! Did you find this helpful?